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Abstract
Endometriosis is a debilitating disease characterized by the growth of ectopic endometrial tissue. It
is widely accepted that angiogenesis plays an integral part in the establishment and growth of
endometriotic lesions. Recent data from a variety of angiogenesis-dependent diseases suggest a
critical role of bone marrow–derived endothelial progenitor cells (EPCs) in neovascularization. In
this study we examined the blood levels of EPCs and mature circulating endothelial cells in a
mouse model of surgically induced endometriosis. Fluorescence-activated cell sorting analysis
revealed elevated levels of EPCs in the blood of mice with endometriosis compared with control
subject that underwent a sham operation. EPC concentrations positively correlated with the
amount of endometriotic tissue and peaked 1 to 4 days after induction of disease. In a green
fluorescent protein bone marrow transplant experiment we found green fluorescent protein–
positive endothelial cells incorporated into endometriotic lesions but not eutopic endometrium, as
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trevealed by flow cytometry and immunohistochemistry. Finally, treatment of endometriosis-
bearing mice with the angiogenesis inhibitor Lodamin, an oral nontoxic formulation of TNP-470,
significantly decreased EPC levels while suppressing lesion growth. Taken together, our data
indicate an important role for bone marrow–derived endothelial cells in the pathogenesis of
endometriosis and support the potential clinical use of anti-angiogenic therapy as a novel
treatment modality for this disease.
Endometriosis, or extra-uterine endometrial-like tissue, affects approximately 10% of
women during their reproductive years. The disease causes debilitating pain and severely
affects quality of life with symptoms mimicking those associated with other chronic pain
disorders, such as irritable bowel syndrome and pelvic inflammatory disease. In addition,
endometriosis is closely associated with infertility. The diagnosis is usually made upon
visual inspection of the pelvis during laparoscopy; noninvasive diagnostic tools, such as
ultrasound scanning, can reliably detect only severe forms of the disease, such as ovarian
endometriotic cysts. As a result, women can suffer for 8 to 12 years before receiving a
definitive diagnosis and appropriate treatment. A biomarker of endometriosis would be
invaluable to aid in earlier diagnosis and to monitor therapeutic efficacy.
The treatment options and success rates are limited, partially because of a lack of
understanding of the pathogenesis of endometriosis. Treatments include use of hormonal
drugs to suppress ovarian function, surgical ablation of endometriotic lesions, and, if
necessary, removal of the pelvic organs. In the United States, endometriosis is the third-
leading gynecological cause for hospitalization and is associated with significant costs. In
addition, patients with endometriosis have an increased risk of ovarian cancer and non-
Hodgkin's lymphoma, which adds to the burden of the disease.
Although the pathogenesis of endometriosis remains uncertain, recent studies by our group
and others have demonstrated that the development of a vascular supply is essential for the
establishment and growth of endometriotic lesions. Thus inhibition of angiogenesis has been
suggested as a novel therapeutic approach and has shown promise in preclinical studies.
Neovascularization occurs as a result of local sprouting of endothelial cells, elongation of
pre-existing blood vessels, or de novo vasculogenesis. Elevated local or systemic levels of
angiogenic factors not only result in migration and proliferation of endothelial cells but also
recruit endothelial cells from the bone marrow. Vascular endothelial growth factor (VEGF),
which is highly up-regulated in endometriotic lesions, eutopic endometrium, and peritoneal
fluid of patients with endometriosis, is a strong stimulus for the recruitment of bone
marrow–derived endothelial progenitor cells (EPCs). Elevated VEGF serum levels in
patients with endometriosis have been reported by some researchers but not by others, which
may be due to the short half-life of VEGF of approximately 3 minutes. Considerable debate
currently exists about the contribution of EPCs to neovascularization of tumors. Particular
interest has focused on whether EPCs incorporate into the growing vascular tree and, if so,
to what extent they contribute to neovascularization. VEGF inhibition appears to decrease
levels of EPCs and increase the detachment of mature circulating endothelial cells (CECs)
originating from tumor vasculature. Thus it has been suggested that EPCs and CECs can be
used as surrogate markers for disease progression and efficacy of anti-angiogenic therapy in
tumors.
Endometriosis and tumor growth both require angiogenesis for expansion of mass. Because
previous work has suggested the use of EPCs as an indicator of tumor growth and
regression, in this study we investigated the role of EPCs as potential biomarkers of
endometriosis. We used an established mouse model of surgically induced endometriosis to
measure levels of CECs and EPCs. Further, we used a bone marrow transplantation model to
quantify the extent of EPC incorporation into the newly forming vasculature of growing
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EPC and CEC levels.
Material and Methods
Animal Handling
All procedures were performed in the animal facility at Children's Hospital, Boston, MA.
All animal handling and procedures were performed in accordance with federal, local, and
institutional guidelines and were approved by the Institutional Animal Care and Use
Committee of Children's Hospital. Eight-week-old female 129 × 1/SvJ mice were purchased
from Jackson Laboratories (Bar Harbor, MN); 129S6/SvEvTac mice were purchased from
Taconic Farms (Hudson, NY), and C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA). C57BL/6J-GFP-mice were a generous gift from Dr. Taturo
Udagawa. The mice were caged in groups of five to 10 with free access to chow and water;
they were acclimated for 3 weeks before any experiment. The animal room was kept
constantly at 26°C, 38.5% humidity, with a 12-hour light, 12-hour dark cycle (7:30 AM to
7:30 PM). Mice received no hormonal treatment.
Induction of Endometriosis
Mice were randomly taken from different cages to minimize any potential effects of the
stage of the estrous cycle, which was determined by vaginal smears as previously described.
Consequently, the stages were evenly distributed across the different groups in all
experiments (data not shown). All surgical procedures were performed under inhalational
anesthesia with isoflurane (Baxter, Deerfield, IL), and mice were observed until they fully
recovered. Endometriosis was surgically induced as described previously. Briefly, the
uterine horns were removed through a midline abdominal incision and opened longitudinally
in a Petri dish containing warmed 0.9% saline solution. Four or six biopsy specimens (2 mm
in diameter) were obtained with use of a dermal biopsy punch (Miltex, Bethpage, NY), and
the lesions were autotransplanted to the peritoneal wall with the endometrial side facing the
peritoneum using a braided 7–0 silk suture (Ethicon, Somerville, NJ). The wound was
closed with a 5–0 suture (Ethicon). Identical procedures were performed in the “sham
group” except that sutures alone were inserted instead of endometrial tissue. Mice in the
“control group” did not undergo surgery. For initial experiments (Figure 1), blood was taken
1 week after inoculation with endometriosis. For all of the other experiments, blood was
drawn and mice were sacrificed at the indicated time points. At the end of the experiment,
lesions were measured at their implantation site as described previously: two perpendicular
diameters (D1, D2) of each lesion were measured with a caliper to the nearest tenth of a
millimeter. Lesion volumes were determined using the formula for a sphere (volume = D1 ×
D2 × π/4). Lesions were then excised for further processing. In some groups of mice the
uteri also were removed for further analysis (described in a later section).
Lodamin Treatment
129S6/SvEvTac mice were divided into three groups (“endometriosis,” “sham,” and
“control”; n = 20/group). Half of the mice received 15 mg/kg Lodamin, an oral formulation
of the angiogenesis inhibitor TNP-470, or vehicle daily by oral gavage for 14 days. Mice
were monitored daily for changes in weight. Daily vaginal smears were taken, and uterine
horns were removed at the end of the experiment to determine the potential effect of
Lodamin on estrous cycling. In the bone marrow transplantation experiments, C57BL/6J
mice with transplanted green fluorescent protein (GFP) bone marrow received endometriotic
tissue from wild-type C57BL/6J mice.
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Bone marrow transplantation was performed as described previously. In brief, bone marrow
was harvested from C57BL/6J-GFP mice. The donor mice were euthanized using carbon
dioxide, and their femurs were dissected and then flushed with 1 mL sterile 0.9% saline
solution to collect bone marrow. Anesthetized recipient C57BL/6 mice (Charles River
Laboratories) were lethally irradiated with 950 Gy. The harvested GFP bone marrow was
then injected into the retro-orbital plexus of into the irradiated recipients in 100 μL 0.9%
saline solution. The bone marrow was allowed to engraft for 6 weeks. Engraftment was
verified by GFP-positive blood samples before endometriosis induction.
Flow Cytometry Analysis of Circulating Endothelial Cells
Circulating EPCs and CECs were measured in the peripheral blood of all of the mice. After
induction of anesthesia using isoflurane, 500 μL to 1000 μL of blood was collected by retro-
orbital puncture and anticoagulated with use of sodium citrate. Blood was kept on ice until
processing, and 150 μL of blood was used to quantify circulating endothelial cells using
four-color flow cytometry as previously described. Red blood cells were lysed using
FACSLyse Solution (BD Biosciences, San Jose, CA), according to the manufacturer's
directions. For the fluorescence-activated cell sorting analysis of GFP-positive cells in
tissue, eutopic endometrium and endometriotic lesions were taken from mice that had
undergone a bone marrow transplantation and wild-type mice. Tissue was incubated in
Dispase 2 (Roche, Nutley, NJ) for 30 minutes at 37°C per the manufacturer's instructions to
dissociate tissue into single-cell suspensions, re-suspended in Dulbecco's modified Eagle's
medium with 10% fetal bovine serum to neutralize enzymes, and washed in PBS with 1%
bovine serum albumin before staining with antibodies and performing fluorescence-
activated cell sorting analysis.
The following directly conjugated antibodies were used to detect EPCs and CECs in
peripheral mouse blood: anti-mouse CD45-PerCP, CD31-APC (platelet/endothelial cell
adhesion molecule-1), Flk-1-PE (mouse VEGFR-2; all BD Biosciences, San Jose, CA), and
CD133-fluorescein isothiocyanate (Prominin-1; eBioscience, San Diego, CA). Tissue was
stained with the same antibodies except the CD133 fluorescein isothiocyanate antibody.
Flow cytometry was performed using a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA) and acquired data were analyzed with FLOWJO flow cytometry analysis software
(Treestar, Ashland, OR), with analysis gates designed to remove residual platelets and
cellular debris. Fluorescence minus one control subjects were used for gating. Between
500,000 and 1000,000 events were counted in each sample. SV40-transformed murine
endothelial (MS-1) cells were spiked into blood samples as a positive control for
compensation and gating purposes.
Circulating endothelial cells in mouse peripheral blood were assessed using flow cytometry
and then classified into mature (CECs: CD45−, VEGFR-2+, CD31+, CD133−) and bone
marrow–derived progenitor endothelial cells (EPCs: CD45−, VEGFR-2+, CD31+, CD133+)
as previously described.
Immunohistochemistry
Immunohistochemical staining was carried out on 8-μm frozen sections. For CD31-Cy3
staining, sections were dried for 2 to 3 hours at room temperature and circled with an
Immedge Pen (Vector Laboratories, Burlingame, CA). Sections were immersed in 0.3%
Triton X-100 PBS (T-PBS), washed twice with PBS, and then blocked for 1 hour with 5%
goat serum (Jackson ImmunoResearch, West Grove, PA) in PBS + 0.3% Triton X-100 +
0.01% bovine serum albumin + 0.01% Thimerosal. The same solution without goat serum
was used to dilute antibodies. Incubation with primary antibody (rat anti-mouse CD31,
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t1:500, BD Biosciences) was carried out overnight. Slides were then washed with T-PBS and
incubated with secondary antibody (Cy3-goat anti-rat 1:400, Jackson ImmunoResearch) for
4 to 5 hours. Slides were then washed with T-PBS and fixed with 4% paraformaldehyde for
15 minutes. The final washes with PBS were done before mounting with Vectashield
Mounting Medium with DAPI (Vector Laboratories) according to the manufacturer's
instructions.
Uterine horns and ovaries were removed from mice in all groups after Lodamin treatment.
Tissues were snap frozen in liquid nitrogen and mounted in OCT embedding medium
(Thermo Fisher Scientific, Waltham, MA). Sections that were 5- to 7-μm thick were cut on a
cryostat machine and stained with H&E.
Statistics
All statistical comparisons were done using SigmaStat software (Aspire Software
International, Leesburg, VA) as previously described. The number of mature CECs and
EPCs detected in each mouse was expressed as absolute number of cells per microliter of
blood analyzed. Mean CEC and EPC values were then calculated and compared between the
different groups. Means and Student's t-test for parametric data or median and rank-sum test
for nonparametric data were applied to compare groups. EPCs in whole blood were
compared using one-way analysis of variance (analysis of variance) with posthoc testing
based on the Bonferroni procedure to minimize type I errors (false-positive results) due to
multiple group comparisons. Lesion size was compared with use of repeated-measures
analysis of variance.
Results
EPC Levels Are Elevated in a Mouse Model of Endometriosis
To examine the levels of EPCs in a mouse model of endometriosis, we initially measured
EPC counts by flow cytometry in C57BL/6 mice with four syngeneic endometriotic lesions.
As we have previously described, EPCs were identified by their expression of three cell
surface markers including CD31 (endothelial marker), Flk-1 (VEGFR-2, endothelial
marker), and CD133 (Prominin-1, stem cell marker) and the absence of CD45
(hematopoietic cell marker) (see Supplemental Figure S1 at http://ajp.amjpathol.org). To
distinguish between CECs and EPCs, further characterization was done by gating on CD133
and CD31 expression. Similar to previous reports, in a typical experiment with C57BL/6
mice we found 0.2 to 0.5 EPC per microliter of blood and five to 10 CECs per microliter of
blood. In the presence of four and six lesions, a highly statistically significant overall
difference between the three groups was observed 1 week after endometriosis surgery (four
lesions: F = 51.48, P < 0.0001, Figure 1A; six lesions: F = 8.41, P = 0.001, Figure 1B).
However, the difference between the endometriosis and sham groups were only marginally
significant or not significant.
Because various inbred murine genetic backgrounds have been demonstrated to have
variable angiogenic responses, we chose to examine one of the most angiogenic strains, 129/
SvJ mice. Thus we implanted six lesions per mouse into 129/SvJ mice, which have been
shown to have baseline higher circulating EPC levels. Our studies demonstrated a significant
overall mean difference between groups (Figure 1C) (F = 7.39, P = 0.003). Statistical
analysis further indicated significantly higher circulating blood EPC levels in the
endometriosis group compared with control subjects (P = 0.007) or compared with mice that
underwent a sham operation (P = 0.007) (Figure 1C). No significant difference was detected
between sham treated mice versus control subjects (P = 0.99).
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To determine whether the numbers of EPCs or CECs fluctuated over time after the
implantation of endometriotic lesions, mice were terminally bled on various days after
disease initiation. We found a highly significant change in lesion area over time (F = 15.78,
P < 0.001), with posthoc analysis revealing a significant reduction in the first 10 days (P =
0.04) and then a dramatic increase from day 10 to day 28 (P < 0.001). We next examined the
changes in mean EPCs per microliter of whole blood between sham and endometriosis
groups at specific time points. Our results indicated overall significantly greater circulating
EPC levels in the endometriosis group (F = 10.54, P = 0.002) (Figure 2B) with significant
differences at 1 day (P = 0.008), 4 days (P = 0.03), and 10 days (P = 0.04) but no
differences at 7 days (P = 0.48), 14 days (P = 0.30), or 28 days (P = 0.47).
We then investigated CEC levels in mice that had endometriosis versus mice that underwent
a sham operation over time. Overall, significantly higher CEC levels were found in the
endometriosis group (F = 4.21, P = 0.04) (Figure 2C), which was confirmed by posthoc
analysis for day 1 (P < 0.001), but not thereafter.
Bone Marrow-Derived Cells Incorporate into the Vasculature of Endometriotic Implants
Endometriotic lesions were implanted into irradiated wild-type mice transplanted with GFP-
expressing bone marrow. Endothelial cells in the circulation, in the endometriotic lesions,
and in the uterine tissue were quantified at various time points after surgery. Uterine tissue
and endometriotic lesions were isolated and dissociated into single cell suspensions, and
endothelial cells were identified using flow cytometry by the expression of two different cell
surface markers (CD31+ and VEGFR2+) and exclusion of a hematopoietic cell surface
antigen (CD45−) (Figure 3A). We detected a highly significant increase over time in the
numbers of endothelial cells incorporated into the endometriotic lesions at 21 days (F =
31.97, P < 0.001) but no change in uterine tissue (F = 1.73, P = 0.21).
The percentage of GFP-positive bone marrow–derived cells was significantly elevated in
endometriotic lesions after 21 days (F = 30.62, P < 0.001) but remained constant in uterine
tissue (F = 0.88, P = 0.48) (Figure 3B). To determine whether GFP bone marrow–derived
cells were endothelial cells, we analyzed GFP+ cells that were also VEGFR2 and CD31
positive but negative for CD45 (Figure 3C). None of these cells could be detected in the
endometriotic lesions on the day after the transplantation. Two-way analysis of variance
confirmed a highly significant increase over time in the percentage of GFP-positive
endothelial cells in endometriotic tissue (F = 33.06, P < 0.001) and in uterine tissue (F =
21.69, P = 0.003). Furthermore, incorporation of GFP-positive cells into the vasculature of
endometriotic lesions was confirmed by immunofluorescence with an antibody to CD31, an
endothelial cell specific marker that co-localized with GFP expression (Figure 3D). These
studies confirmed the presence of endothelial progenitor cells incorporated into
endometriotic lesions.
Lodamin Inhibits the Up-Regulation of EPCs and CECs
Anti-angiogenic therapy has been shown to suppress endometriotic growth in various mouse
models. Lodamin is an oral nontoxic formulation of TNP-470, one of the most potent
angiogenesis inhibitors known to date. Cohorts of wild-type mice were either designated as
control (untouched) or had sham surgery or endometriotic lesions implanted. Mice were then
treated daily with either 15 mg/kg Lodamin or vehicle alone by oral gavage. Weight loss
among the different cohorts was not statistically significant, indicating the lack of toxicity
with daily Lodamin treatment for 1 week (data not shown). After 1 week of treatment, blood
was drawn to measure both CEC and EPC concentrations. Statistical analysis indicated
significantly lower CECs per microliter of whole blood for treatment compared with vehicle
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tin the endometriosis group (P = 0.02) but no significant difference between vehicle and
treatment for control (P = 0.09) or sham (P = 0.21) groups (Figure 4A).
When we looked at EPCs, overall highly significant differences were observed (F = 6.72, P
= 0.006), with significantly lower EPCs per microliter after treatment of the endometriosis
(P < 0.001), but no significant differences in the control group (P = 0.11) or the sham group
(P = 0.07) (Figure 4B). This finding could indicate that anti-angiogenic therapy with
Lodamin suppresses the mobilization of both circulating endothelial cells and endothelial
progenitor cells in the presence of an angiogenesis-dependent disease.
When the lesion size was measured after 1 week of Lodamin treatment, results indicated a
significantly smaller lesion area in the Lodamin group compared with vehicle (1.74 mm2
versus 1.41 mm2, F = 7.99, P = 0.022) (Figure 4C).
Discussion
In the present study we show that circulating endothelial progenitor cells are elevated in an
established mouse model of endometriosis and provide evidence that these cells incorporate
into the growing vasculature of the endometriotic lesions. EPC up-regulation appears to be
highest during early lesion establishment, coinciding with increased vascular growth as
previously demonstrated. However, treatment with the potent angiogenesis inhibitor
Lodamin resulted in a significant inhibition of this surge of circulating EPCs and subsequent
suppression of lesion growth. These findings imply a potential role for EPCs in the
angiogenesis-dependent growth of endometriotic lesions and may indicate the use of EPCs
as a biomarker of disease progression and surrogate marker of treatment efficacy.
Endometriosis is similar to tumors in that it requires blood vessel growth for disease
establishment and progression. Although the exact mechanisms are unknown, angiogenesis
has been proposed to occur in endometriosis through classic mechanisms such as
proliferation of endothelial and supporting cells, intussusception, and elongation of existing
blood vessels. In our current study, we demonstrate for the first time another possible
mechanism, the incorporation of bone marrow–derived circulating endothelial progenitor
cells into the growing vascular tree. Blood EPC levels rose within 2 days of “disease”
induction and peaked during the first 10 days, in a manner that was inversely correlated with
the size of the lesions.
Considerable debate exists about the role of EPCs, in particular regarding the extent and
significance of their incorporation into tumor vasculature. In our study, we found that up to
37% of all endothelial cells in the lesions were bone marrow–derived 1 week after
transplantation. No significant increase of general bone marrow–derived cells in the uterus
was observed during this period. However, the percentage of bone marrow–derived
endothelial cells did increase over time, which may be a result of changes in the estrous
cycle in these animals. Human studies have shown higher blood EPC levels during the
follicular and the luteal phase, but in this model, we did not see estrous cycle–related
differences in blood EPC levels (data not shown). Eggermont et al demonstrated in a
xenotransplant model that human lesions contained murine CD31-positive cells as early as
day 5 after implantation, peaking around day 15. Because host endothelial cells invaded the
interface between the peritoneal stroma and the lesion, they suggested that the source of the
endothelial cells most likely was in the proliferating surrounding blood vessels. Our data
suggest that bone marrow–derived endothelial cells may contribute to this process of blood
vessel growth, especially during early lesion establishment.
Endometriosis is a chronic, progressive disease that frequently presents with multiple sites
of extra-uterine tissue in the peritoneal cavity. Pro-angiogenic factors such as VEGF, basic
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tfibroblast growth factor, and IL-8 are elevated in endometriotic tissue, peritoneal fluid, or
serum of patients with endometriosis. VEGF is a well-studied mitogen for endothelial cells
and strongly increases vascular permeability. It has been previously demonstrated that
VEGF plays a significant role in the mobilization of bone marrow– derived progenitor cells
for postnatal neovascularization.
Assuming that VEGF is one of the main stimuli for the recruitment of EPCs in this model,
our current data support our previous findings that showed high VEGF levels in the
transplanted lesions during the first week after transplantation. This rise and subsequent fall
in EPC concentration and VEGF expression could be explained by a hypoxic environment
after the lesions lose their blood supply followed by a normoxic one once the lesions acquire
new blood vessels. In fact, we have previously demonstrated a concomitant rise in levels of
hypoxia inducible factor-1 α and its downstream target, VEGF, in these lesions during the
first few days after transplantation. Concentrations of both molecules decline thereafter
when neovascularization results in the delivery of oxygen and nutrients. The small, delayed
rise in blood EPC levels in the mice that underwent a sham operation is possibly due to
wound healing in these animals. Other factors have been shown to stimulate EPC
recruitments such as stromal cell-derived factor-1, placental growth factor, and matrix
metalloprotease-9. Interestingly, they all have been associated with endometriosis.
Blood levels of mature endothelial cells also rose in both mice that underwent a sham
operation and in mice with endometriosis, although this effect was delayed in the sham
group. We speculate that wound healing, mainly of the abdominal wall and uterine stump,
resulted in the shedding of these cells from the local tissue in all animals. The fact that this
phenomenon occurred earlier in the endometriosis group supports this theory, because
transplantation increases the tissue burden undergoing regeneration. CEC concentrations in
both groups were similar after a few days, suggesting that most of the endothelial cells
originating from the transplanted lesions had gone.
Anti-angiogenic therapy may have a role as a novel therapeutic approach in patients with
endometriosis. However, potential teratogenicity and inhibitory effects on the reproductive
system demonstrated by some angiogenesis inhibitors are posing a significant hurdle to the
clinical testing of angiogenesis inhibitors in patients with endometriosis. We previously
demonstrated that the endogenous angiogenesis inhibitor endostatin and its fragment mP-1
had no negative effects on the reproductive cycle and offspring of mice, while endometriotic
growth was suppressed. TNP-470, a synthetic fumagillin analog, is a very powerful
angiogenesis inhibitor that has been shown to inhibit endometriotic growth but that caused
neurotoxicity in clinical trials. Lodamin is an oral, nontoxic form of the fumagillin
derivative TNP-470, which inhibits tumor growth and angiogenesis in mice. Possible
TNP-470 mechanisms on endothelial cells include affecting the cell cycle through p53
activation by binding to methionine aminopeptidase (MetAP-2), preventing Rac1 activation
and induction of p21 (CIP/WAF).
In our current study we found that Lodamin suppressed the levels of EPCs in the blood of
mice that had endometriosis while inhibiting growth of endometriotic lesions. We have seen
a similar effect with caplostatin (unpublished data), an injectable, nontoxic formulation of
TNP-470 that inhibited endometriotic growth and angiogenesis. TNP-470 has been shown to
inhibit VEGF-induced endothelial cell growth, migration, and vascular hyperpermeability.
In vitro data suggest that VEGF expression by tumor cells is inhibited by TNP-470. Because
VEGF is considered to play a central role in bone marrow recruitment, it is conceivable that
TNP-470 treatment inhibits VEGF expression in the endometriotic lesions, resulting in a
reduced stimulus for EPC mobilization. We have previously demonstrated that VEGF is
highly up-regulated in endometriotic tissue through hypoxia inducible factor-1 α. Therefore
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tif the TNP-470 derivative Lodamin inhibits this pathway it could explain the effect on EPC
levels in the treated animals. In fact, Lodamin inhibits VEGF-induced angiogenesis in a
mouse corneal micropocket assay. Treatment with Lodamin resulted in the arrest of the
estrous cycle at metestrus (data not shown). Therefore it is conceivable that the potential
effect of the drug on estrogen levels also may affect EPC (and CEC levels). This question is
currently under investigation.
In summary, we demonstrate that bone marrow–derived endothelial cells contribute to
neovascularization in a mouse model of endometriosis. These findings highlight the
importance of angiogenesis in the establishment and growth of endometriotic lesions, and
they also support the hypothesis that endothelial progenitor cells are involved in the
pathogenesis of the disease. From a clinical perspective it will be highly interesting to
investigate EPC and CEC levels in women who have the disease and the effect of therapy on
these levels. If circulating endothelial progenitor and mature endothelial cells are elevated in
patients, they may be promising and much needed biomarkers for both diagnosis and
therapeutic efficacy.
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tFigure 1.
Blood EPC numbers in mice. Female mice received endometriotic (black columns) or sham
lesions (gray columns) during abdominal surgery or were not operated upon (control
subjects, white columns). Whole blood was taken after 1 week and stained for EPC markers
(flow cytometry). Female C57BL/6 mice received four lesions (A) or six lesions (B) (*P <
0.05; **P < 0.001, posthoc Bonferroni test). Female 129SvJ mice received six lesions (C).
All experiments were performed with n = 10 per group. Values shown are mean ± SEM (*P
< 0.05; **P = 0.007, posthoc Bonferroni test).
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Blood levels of endothelial cells over time. Whole blood was collected from mice with six
endometriotic lesions after different time points (n = 5 per time point and group). A:
Following blood collection, endometriotic lesions were measured with a caliper using the
formula of an ellipse as previously described. Values shown are mean ± SEM. B: EPCs
stained negative for CD45 and positive for CD31, VEGRR-2, and CD133 (*P ≤ 0.04; **P =
0.008; posthoc Bonferroni test). C: CECs stained negative for CD45 and CD133 and
positive for CD31 and VEGFR-2 [endometriosis group (black squares); sham operated
group (white diamonds)] (**P < 0.001; posthoc Bonferroni test).
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Endothelial cells in endometriotic lesions. After irradiating with lethal doses, mice received
GFP+/+ bone marrow from donor mice. Six weeks later, endometriotic lesions from wild-
type animals were implanted into these mice. Lesions and uterine tissue were removed at
different time points from different mice (n = 5 per group and time point), digested, and
single cell suspensions were stained and measured using flow cytometry [endometriotic
lesions (black squares); uterine tissue (white diamonds)]. A: Percentage of CD45−, CD31+,
and VEGFR-2+ endothelial cells of all cells were measured. B: Percentage of GFP+ cells of
all cells measured. C: Percentage of CD45−, CD31+, VEGFR-2+, and GFP+ endothelial
cells. Values shown are mean ± SEM (*P < 0.003; **P < 0.001; posthoc Bonferroni test).
D: Immunohistochemistry of wild-type endometriotic lesions in irradiated mice with
transplanted GFP+ bone marrow. GFP fluorescence (middle panel) and after staining for
CD31 (Cy-3; left panel). Fluorescent confocal microscopy showed some co-localization of
GFP+ and CD31+ cells (right panel; bar = 50 μmol/L).
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Effect of antiangiogenic treatment on EPCs and CECs. Female 129 SvJ mice underwent
endometriosis or sham surgery or no surgery (control subjects) (n = 10 per group). Half of
the mice of each group received 15 mg/kg Lodamin (Tx; black columns), an oral, nontoxic
form of the angiogenesis inhibitor TNP-470, over 7 days. Control subjects received vehicle
(V; white columns). Whole blood was taken at the end of the experiment, stained for (A)
CEC markers (CD45−, CD31+, VEGFR-2+, CD133−) (*P = 0.02; two-way analysis of
variance) and (B) EPC markers (CD45−, CD31+, VEGFR-2+, CD133+) (**P < 0.001; two-
way analysis of variance) and measured using flow cytometry. C: Endometriosis-like
lesions were measured with a caliper using the formula of an ellipse. Mean cross-sectional
area of endometriosis-like lesions (n = 6 lesions) of mice treated with vehicle or Lodamin
(*P = 0.022; repeated-measures analysis of variance). Values shown are mean ± SEM.
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